All In Biotech

Drug Trial Radar · NCT05631795

Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment

ALPelisib INdia Safety STudy (ALPINIST): A Phase IV, Prospective, Multicenter, Open-label, Non-comparative, Interventional Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR Positive, HER2-negative, Advanced Breast Cancer (aBC) With a PIK3CA Mutation, Whose Disease Has Progressed on or After Endocrine Based Treatment.

Last checked: Nov 20, 2026Latest source record: Jul 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

40

Actual

Start

Aug 9, 2022

Primary completion

Jun 12, 2025

Study completion Jun 12, 2025

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Nov 30, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to determine the safety of alpelisib plus fulvestrant in men and post-menopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, advanced or metastatic breast cancer (aBC) with a PIK3CA mutation, whose disease had progressed on or after endocrine-based treatment.

Conditions

  • Advanced Breast Cancer

Interventions

  • AlpelisibDrug

    Film coated tablet for oral use. Participants will be treated with 300 mg of alpelisib once daily starting on Cycle 1 Day 1

  • FulvestrantDrug

    Injection for intramuscular administration. Participants will be treated with fulvestrant 500 mg on Cycle 1 Day 1 and Day 15, and Day 1 of every cycle thereafter in a 28-day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With at Least One On-treatment Adverse Events (AEs)Time frame: From start of treatment up to 30 days after last dose of study treatment, assessed up to approximately 7 months

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Ahmedabad, India

  • Novartis Investigative Site

    Kolkata, India

  • Novartis Investigative Site

    Guwahati, Assam, India

  • Novartis Investigative Site

    Surat, Gujarat, India

  • Novartis Investigative Site

    Thalassery, Kerala, India

  • Novartis Investigative Site

    Trivandrum, Kerala, India

  • Novartis Investigative Site

    Bhopal, Madhya Pradesh, India

  • Novartis Investigative Site

    Mumbai, Maharashtra, India

  • Novartis Investigative Site

    Nagpur, Maharashtra, India

  • Novartis Investigative Site

    Pune, Maharashtra, India

  • Novartis Investigative Site

    New Delhi, National Capital Territory of Delhi, India

  • Novartis Investigative Site

    Hyderabad, Telangana, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.